Loading...
Market
Primary challenge in adoption of new HIV prevention injections by end of 2025?
2
Resolution / Starting Odds
Cost • 25%
Distribution • 25%
Adherence • 25%
Regulatory Approval • 25%
Reports from global health organizations and research studies
Story
New HIV Prevention Injections Offer Six Months Protection; 100% Effective, Gilead to Sell Generics Ahead of World AIDS Day
Dec 1, 2024, 04:00 PM
Recent advancements in HIV prevention include long-acting injections that provide protection for up to six months per shot. As World AIDS Day approaches, experts are evaluating the implications of these new tools in combating HIV. A study has shown that a twice-yearly injection was 100% effective in preventing HIV infections among women and nearly as effective in men. Pharmaceutical company Gilead has announced plans to sell affordable generic versions of the medication in 120 countries with high rates of HIV. Despite these advancements, experts emphasize the importance of equitable access and addressing adherence challenges to maximize the impact of HIV prevention efforts.
View original story
Similar markets
Cost • 25%
Regulatory approvals • 25%
Manufacturing capacity • 25%
Public awareness • 25%
Cost of the drug • 25%
Distribution and accessibility issues • 25%
Lack of awareness and education • 25%
Regulatory hurdles • 25%
Lenacapavir • 25%
Cabotegravir • 25%
Both equally • 25%
Neither dominates • 25%
Funding Shortfalls • 25%
Public Awareness • 25%
Access to Healthcare • 25%
Other • 25%
Cost • 25%
Distribution • 25%
Regulatory approval • 25%
Adherence • 25%
Funding issues • 25%
Logistical challenges • 25%
Public resistance • 25%
Other • 25%
Supply chain issues • 25%
Regulatory hurdles • 25%
Vaccine hesitancy • 25%
Competition from other vaccines • 25%
Fewer than 10 countries • 25%
10 to 20 countries • 25%
21 to 30 countries • 25%
More than 30 countries • 25%
Approved in UK only • 25%
Approved in UK and EU • 25%
Approved in UK, EU, and USA • 25%
Not approved in any major market • 25%
Stigma and Discrimination • 25%
Access to Medication • 25%
Lack of Funding • 25%
Ineffective Policies • 25%
Higher adoption than oral PrEP • 25%
Equal adoption to oral PrEP • 25%
Lower adoption than oral PrEP • 25%
Data not sufficient to determine • 25%
Lenacapavir adoption rate is less than 25% • 25%
Lenacapavir adoption rate is 25% to 50% • 25%
Lenacapavir adoption rate is 50% to 75% • 25%
Lenacapavir adoption rate is more than 75% • 25%